A Pilot Study of NovoTTF-100A for Recurrent Atypical or Anaplastic Meningioma

Full Title

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma


Progressive meningioma continues to grow despite surgery and/or radiation therapy. The purpose of this study is to assess the use of a device called the NovoTTF-100A System for treating progressive meningioma. This portable device is approved for treating a form of brain cancer called glioblastoma multiforme, but its use for treating meningioma is considered investigational.

Patients wear the sticky pads of the NovoTTF-100A System on their scalp. The device transmits electrical fields through the skull which are intended to kill cancer cells. Patients can learn how to put on the device at home and can wear it throughout the day while they go about their regular activities.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have progressive grade II (atypical) or grade III (anaplastic) meningioma that has continued to grow despite radiation therapy.
  • At least 4 weeks must have passed since radiation therapy, surgery, or other therapy and entry into the study.
  • Patients with an implanted pacemaker, defibrillator, vagus nerve stimulator, deep brain stimulator, or arrhythmia will be enrolled only upon approval of the investigator. (The electrical fields of the NovoTTF-100A System may interfere with other medical devices.)
  • This study is open to patients ages 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Thomas Kaley at 212-639-5122 or the Brain Tumor Hotline at 212-639-6767.





Disease Status

Relapsed or Refractory